EVONIK INDUSTRIES AG

Short‑position filings reveal subtle bearish sentiment toward Evonik Industries. Explore how regulatory shifts, R&D lag, and green‑chemistry growth shape risk and opportunity.

Explore how BASF’s €22 offer could reshape Evonik’s future, blending low‑emission goals, regulatory hurdles and €250m savings.

Evonik’s MDAX‑strong performance, BASF bid rejection, and new voting‑rights update keep investors focused on strategic shifts.

Explore how BASF’s proposed offer for Evonik could reshape the European specialty‑chemicals market and what it means for investors amid rising energy costs.

Short‑sale filings for Evonik Industries AG reveal stable, low‑volume speculative interest, underscoring the specialty chemicals sector’s resilience amid 2026 market shifts.

Short‑sale data on Evonik Industries reveals ~1% of shares shorted, matching market norms and MDAX pullback—valuable insight for investors.

Evonik Industries’ 2025 restructuring will cut 3,200 jobs, focus on high‑growth Asia and the Americas, and boost long‑term shareholder value.

MDAX rises 0.48% as digitalisation, supply‑chain resilience and commodity sensitivity shape German stocks – key movers like Nemetschek SE and Schaeffler lead the way.

Explore Evonik Industries’ share performance over three years: a modest decline amid stable market cap, highlighting commodity pressures, dividends, and sector resilience.

German equity markets stay muted as high oil, chemical downgrades weigh on energy and banking stocks, while steel and defense firms benefit from US and Japanese demand.